Presentations will be delivered by experts from a wide variety of leading research groups including Pfizer, GSK, and Bio-Techne, along with co-hosts IPA, ACROBiosystems, and Curia. SALT LAKE CITY, ...

Swiss oncology firm Veraxa Biotech is set to go public in the US through a merger with Voyager Acquisition Corp, a healthcare ...

Phase 1 trial of TGW101 in advanced solid tumors is enrolling to assess safety and pharmacokinetics and define the maximum ...

Key treatments for Alzheimer’s, rare cancers, and infectious diseases are under review, with new vaccines and therapies like ...

Sanofi’s development of an oral spin on Humira’s mechanism has hit a setback. | Sanofi’s development of an oral spin on ...

Irritable bowel syndrome, chronic itching, asthma and migraine are in many cases hard-to-treat conditions. They have in ...

New research suggests that lingering cell wall fragments from the Lyme disease bacterium, Borrelia burgdorferi, may be responsible for persistent symptoms long after antibiotic treatment.

Scientists believe they know what causes the treated infection to mimic chronic illness: the body may be responding to remnants of the bacteria that causes Lyme that tend to pool in the liver and ...

Irritable bowel syndrome, chronic itching, asthma and migraine are in many cases hard-to-treat conditions. They have in ...

BERLIN (Reuters) -Swiss biotech investor Xlife Sciences AG said on Wednesday its portfolio company Veraxa Biotech AG would list on U.S. exchange Nasdaq in a $1.64 billion merger deal with a ...

Long a lobbying powerhouse in Washington, pharma’s struggling to settle on a strategy for defending itself, according to six industry lobbyists and three company officials who spoke to POLITICO. All ...

IDO1 and PDL1 are immune checkpoints with key roles in immune system regulation. Their relevance stems from their ability to suppress T-cell function. T-cells are vital to the body’s immune response ...